NEJM Report Finds HPV Test More Effective Than Pap in Determining Cervical Cancer Risk

The study, which involved more than 10,000 Canadian women age 30-69, found that the HPV test's sensitivity -- its ability to accurately identify women with pre-cancerous cervical cells or cancer -- was 94.6 percent, compared to 55.4 percent for the Pap. HPV (humanpapilloma virus) is the primary cause of cervical cancer.

This seminal study used QIAGEN's Hybrid Capture(R) 2 High-Risk HPV DNA test -- the only such test that is both CE-marked in Europe and approved by the U.S. Food and Drug Administration(1). The molecular diagnostic test was developed by Digene Corp., now part of QIAGEN N.V. (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA). The performance of QIAGEN's HPV test has been validated in studies that included more than 300,000 women.